"The outlook for cystic fibrosis drug development has changed dramatically," says Robert Beall, PhD, president and CEO of the Cystic Fibrosis Foundation. Ten years ago, there were just five drugs in the pipeline. Now there are more than 30, ranging from ion transport modulators that help correct CF’s underlying genetic defect to inhaled antibiotics that help stave off infections to novel anti-inflammatory drugs that promise to reduce the lung scarring associated with the disease. (See Exhibit 1.)
Much of the credit goes to Beall and his foundation, which has pioneered the notion of venture philanthropy, providing seed...







